ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Top Brokers

More Brokers

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
FTSE 100
8,171.12
0.61%
Dow Jones
39,308.00
-0.06%
Gold vs US Dollar
2,359.54
1.26%
Brent Oil
86.91
0.54%
Bitcoin
60,185.00
-2.97%
Pepperstone
Advertisement
Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. Canada
  5. TSX
  6. Medicenna Therapeutics Corp (MDNA)

  7. Medicenna Therapeutics Corp (MDNA) News

Medicenna Therapeutics (MDNA)

Medicenna Therapeutics Corp
Date:
Sort by:
 Showing the most relevant articles for your search:TSX:MDNA
DateTimeSourceHeadlineSymbolCompany
26/04/202413:16PR Newswire (Canada)L'Organisme canadien de réglementation des investissements permet la reprise de la négociation - MDNATSX:MDNAMedicenna Therapeutics Corp
26/04/202413:14PR Newswire (Canada)Canadian Investment Regulatory Organization Trade Resumption - MDNATSX:MDNAMedicenna Therapeutics Corp
26/04/202413:09PR Newswire (Canada)Suspension de la négociation par l'Organisme canadien de réglementation des investissements - MDNATSX:MDNAMedicenna Therapeutics Corp
26/04/202413:07PR Newswire (Canada)Canadian Investment Regulatory Organization Trading Halt - MDNATSX:MDNAMedicenna Therapeutics Corp
11/06/202012:00PR Newswire (Canada)Medicenna to Present at Raymond James Human Healthcare Innovation ConferenceTSX:MDNAMedicenna Therapeutics Corp
11/06/202012:00PR Newswire (US)Medicenna to Present at Raymond James Human Healthcare Innovation ConferenceTSX:MDNAMedicenna Therapeutics Corp
29/05/202013:15PR Newswire (US)Medicenna Presents Data on MDNA11, an IL-2 Superkine at ASCO 2020TSX:MDNAMedicenna Therapeutics Corp
29/05/202013:15PR Newswire (Canada)Medicenna Presents Data on MDNA11, an IL-2 Superkine at ASCO 2020TSX:MDNAMedicenna Therapeutics Corp
29/05/202013:05PR Newswire (US)Medicenna Updates Efficacy Results from Phase 2b Recurrent GBM Trial at ASCO 2020TSX:MDNAMedicenna Therapeutics Corp
29/05/202013:05PR Newswire (Canada)Medicenna Updates Efficacy Results from Phase 2b Recurrent GBM Trial at ASCO 2020TSX:MDNAMedicenna Therapeutics Corp
15/05/202012:30PR Newswire (US)Medicenna Announces March 31, 2020 Year-End ResultsTSX:MDNAMedicenna Therapeutics Corp
15/05/202012:30PR Newswire (Canada)Medicenna Announces March 31, 2020 Year-End ResultsTSX:MDNAMedicenna Therapeutics Corp
04/05/202012:00PR Newswire (Canada)Medicenna Announces Upcoming Presentations at the ASCO Annual MeetingTSX:MDNAMedicenna Therapeutics Corp
04/05/202012:00PR Newswire (US)Medicenna Announces Upcoming Presentations at the ASCO Annual MeetingTSX:MDNAMedicenna Therapeutics Corp
15/04/202014:23PR Newswire (Canada)Medicenna Announces Full Exercise of Over-Allotment Option as Part of $40.25 Million Public OfferingTSX:MDNAMedicenna Therapeutics Corp
25/03/202011:00PR Newswire (US)Medicenna's IL-2 Superkine, MDNA19, Demonstrates Best-in-Class Features in a Non-Human Primate StudyTSX:MDNAMedicenna Therapeutics Corp
25/03/202011:00PR Newswire (Canada)Medicenna's IL-2 Superkine, MDNA19, Demonstrates Best-in-Class Features in a Non-Human Primate StudyTSX:MDNAMedicenna Therapeutics Corp
17/03/202013:14PR Newswire (Canada)Medicenna Announces Closing of Public Offering of $35 MillionTSX:MDNAMedicenna Therapeutics Corp
12/03/202013:00PR Newswire (Canada)Medicenna Announces Intention to File Final Short Form ProspectusTSX:MDNAMedicenna Therapeutics Corp
04/03/202014:37PR Newswire (Canada)L'OCRCVM permet la reprise de la négociation - MDNATSX:MDNAMedicenna Therapeutics Corp
04/03/202014:36PR Newswire (Canada)IIROC Trade Resumption - MDNATSX:MDNAMedicenna Therapeutics Corp
04/03/202014:25PR Newswire (Canada)Medicenna Announces Pricing of $35 Million Overnight Marketed Offering of Common SharesTSX:MDNAMedicenna Therapeutics Corp
03/03/202022:14PR Newswire (Canada)Suspension de la négociation par l'OCRCVM - MDNATSX:MDNAMedicenna Therapeutics Corp
03/03/202022:11PR Newswire (Canada)IIROC Trading Halt - MDNATSX:MDNAMedicenna Therapeutics Corp
03/03/202021:35PR Newswire (Canada)Medicenna Announces Overnight Marketed Offering of Common SharesTSX:MDNAMedicenna Therapeutics Corp
13/02/202012:30PR Newswire (US)Medicenna Reports Third Quarter Fiscal 2020 Financial ResultsTSX:MDNAMedicenna Therapeutics Corp
13/02/202012:30PR Newswire (Canada)Medicenna Reports Third Quarter Fiscal 2020 Financial ResultsTSX:MDNAMedicenna Therapeutics Corp
13/01/202012:00PR Newswire (US)Medicenna Reports Compelling Results from Recurrent Glioblastoma Trial When Compared to an Eligibility-Matched Control ArmTSX:MDNAMedicenna Therapeutics Corp
13/01/202012:00PR Newswire (Canada)Medicenna Reports Compelling Results from Recurrent Glioblastoma Trial When Compared to an Eligibility-Matched Control ArmTSX:MDNAMedicenna Therapeutics Corp
08/01/202014:13PR Newswire (US)Medicenna Receives $1.3 Million Through Early Warrant ExercisesTSX:MDNAMedicenna Therapeutics Corp
 Showing the most relevant articles for your search:TSX:MDNA

Your Recent History

AQSE
ISLN.GB
iShares Physical Silver ...
Delayed Upgrade Clock
    ADVFN Logo
    InvestorsHub

    United Kingdom
    Company
    Business
    Popular
    Get The App
    App Store
    Google Play

    Support: +44 (0) 203 8794 460 | support@advfn.com

    By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

    © 2024 ADVFN PLC - All Rights Reserved